Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozoralizumab dosing interval extension and methotrexate dose reduction in rheumatoid arthritis remission/low disease activity
jRCTs031220406Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Oct 2022
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of ozoralizumab in rheumatoid arthritis (RA) (3 arms), sponsored by Taisho Pharmaceutical. Started Oct 2022; status: completed.
02
Drugs
ozoralizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs031220406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220406.